Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 1437
Journal of Clinical & Experimental Pathology received 1437 citations as per Google Scholar report
Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- JournalTOCs
- Cosmos IF
- Ulrich's Periodicals Directory
- RefSeek
- Directory of Research Journal Indexing (DRJI)
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
- world cat
- journal seek genamics
- j-gate
- esji (eurasian scientific journal index)
Useful Links
Recommended Journals
Related Subjects
Share This Page
Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinsons disease
9th World Digital Pathology & Pathologists Congress
Elizabeth C M de Lange, Henk-Jan Drenth, Michael J O Neill, Meindert Danhof and Paulien G M Ravenstijn
Leiden University, Netherlands LAP&P Consultants, Netherlands
ScientificTracks Abstracts: J Clin Exp Pathol
Abstract
Changes in blood-brain barrier (BBB) functionality have been implicated in Parkinson's disease. This study aimed to investigate BBB transport of L-DOPA transport in conjunction with its intra-brain conversion, in both control and diseased cerebral hemispheres in the unilateral rat rotenone model of Parkinson's disease. In Lewis rats, at 14 days after unilateral infusion of rotenone into the medial forebrain bundle, L-DOPA was administered intravenously (10, 25 or 50 mg/ kg). Serial blood samples and brain striatal microdialysates were analyzed for L-DOPA and the dopamine metabolites DOPAC and HVA. Ex vivo brain tissue was analyzed for changes in tyrosine hydroxylase staining as a biomarker for Parkinson's disease severity. Data were analyzed by population pharmacokinetic analysis (NONMEM) to compare BBB transport of L-DOPA in conjunction with the conversion of L-DOPA into DOPAC and HVA, in control and diseased cerebral hemisphere. Plasma pharmacokinetics of L-DOPA could be described by a 3-compartmental model. In rotenone responders (71%), no difference in L-DOPA BBB transport was found between diseased and control cerebral hemisphere. However, in the diseased compared with the control side, basal microdialysate levels of DOPAC and HVA were substantially lower, whereas following L-DOPA administration their elimination rates were higher. Parkinson's disease-like pathology indicated by a huge reduction of tyrosine hydroxylase as well as by substantially reduced levels and higher elimination rates of DOPAC and HVA, does not result in changes in BBB transport of L-DOPA. Taking the results of this study and that of previous ones, it can be concluded that changes in BBB functionality are not a specific characteristic of Parkinson's disease and cannot account for the decreased benefit of L-DOPA at later stages of Parkinson's disease.Biography
Elizabeth C M de Lange has obtained her PhD from Leiden University in 1993 and was tenured in 2004. She is the Head of the Translational Pharmacology Group at Leiden Academic Center for Drug Research (LACDR). She has published more than 100 papers and book chapters and is a Member of the Editorial Board of FBCNS, co-founded and co-chaired several of the international symposia on microdialysis in drug R&D. She is an AAPS Fellow since 2013.
